Theravance Biopharma Inc (TBPH) Cash Flow Statement

The OCF/NI ratio oscillates wildly, from -14.85 in 2026Q1 to 1.51 in 2026Q2, reflecting one-time cash inflows from the royalty divestment rather than recurring conversion. Net income in 2025Q4 and 2025Q2 included large gains, but operating cash flow in those quarters was negative or modest, indicating the gap between accrual earnings and cash generation is largely non-operational. Investors should treat the reported net income as a poor proxy for underlying cash-generating ability.

Excluding the 2025Q2 and 2026Q1 spikes, FCF has been consistently negative, with 2024 quarters averaging around -$3M per quarter. The TTM FCF margin of roughly 4% is misleading because it is inflated by non-recurring royalty monetization; the underlying product business appears to be near break-even at best. The recent 2026Q2 FCF of -$8.9M suggests that without the royalty cushion, the company's cash burn is accelerating as YUPELRI commercialization costs persist.

CapEx/Revenue is consistently below 1%, which is typical for a biotech outsourcing manufacturing and relying on partners like Viatris. This suggests that the company's cash flow trajectory is not constrained by maintenance capital needs but by R&D and SG&A spending. The lack of capex also means that any future growth in YUPELRI would not require significant fixed investment, but it also limits the company's ability to build internal manufacturing capabilities.

The massive positive working capital changes in 2025Q4 and 2025Q2 align with the receipt of royalty monetization proceeds, while the negative swing in 2026Q2 suggests a reversal of those timing benefits. This volatility makes it difficult to assess the underlying working capital cycle, but it appears that the company's cash flow is heavily influenced by the timing of large, non-recurring payments. Investors should monitor whether the 2026Q2 negative swing indicates a return to normal cash burn or a one-time settlement outflow.

The buyback activity is modest relative to the $208M FCF generated in 2025Q2, suggesting that most of the royalty proceeds were retained for debt paydown or future pipeline funding. The absence of dividends is consistent with a company still investing in clinical development. With the pending acquisition by Zymeworks, these capital deployment decisions may become moot, but they indicate a shift toward shareholder returns that could be reversed under new ownership.